183 related articles for article (PubMed ID: 37082446)
1. Comparison of pharmacological inhibitors of lysine-specific demethylase 1 in glioblastoma stem cells reveals inhibitor-specific efficacy profiles.
Stitzlein LM; Gangadharan A; Walsh LM; Nam D; Espejo AB; Singh MM; Patel KH; Lu Y; Su X; Ezhilarasan R; Gumin J; Singh S; Sulman E; Lang FF; Chandra J
Front Neurol; 2023; 14():1112207. PubMed ID: 37082446
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of LSD1 sensitizes glioblastoma cells to histone deacetylase inhibitors.
Singh MM; Manton CA; Bhat KP; Tsai WW; Aldape K; Barton MC; Chandra J
Neuro Oncol; 2011 Aug; 13(8):894-903. PubMed ID: 21653597
[TBL] [Abstract][Full Text] [Related]
3. Preclinical activity of combined HDAC and KDM1A inhibition in glioblastoma.
Singh MM; Johnson B; Venkatarayan A; Flores ER; Zhang J; Su X; Barton M; Lang F; Chandra J
Neuro Oncol; 2015 Nov; 17(11):1463-73. PubMed ID: 25795306
[TBL] [Abstract][Full Text] [Related]
4. Combination LSD1 and HOTAIR-EZH2 inhibition disrupts cell cycle processes and induces apoptosis in glioblastoma cells.
Zhao J; Jin W; Yi K; Wang Q; Zhou J; Tan Y; Xu C; Xiao M; Hong B; Xu F; Zhang K; Kang C
Pharmacol Res; 2021 Sep; 171():105764. PubMed ID: 34246782
[TBL] [Abstract][Full Text] [Related]
5. Role of Lysine-specific Demethylase 1 and Its Small Molecule Inhibitors in Glioblastoma Multiforme Therapy.
Mitra R; Ayyannan SR
Anticancer Agents Med Chem; 2022; 22(18):3062-3085. PubMed ID: 35593350
[TBL] [Abstract][Full Text] [Related]
6. Pharmacologic inhibition of lysine-specific demethylase 1 as a therapeutic and immune-sensitization strategy in pediatric high-grade glioma.
Bailey CP; Figueroa M; Gangadharan A; Yang Y; Romero MM; Kennis BA; Yadavilli S; Henry V; Collier T; Monje M; Lee DA; Wang L; Nazarian J; Gopalakrishnan V; Zaky W; Becher OJ; Chandra J
Neuro Oncol; 2020 Sep; 22(9):1302-1314. PubMed ID: 32166329
[TBL] [Abstract][Full Text] [Related]
7. LSD1-directed therapy affects glioblastoma tumorigenicity by deregulating the protective ATF4-dependent integrated stress response.
Faletti S; Osti D; Ceccacci E; Richichi C; Costanza B; Nicosia L; Noberini R; Marotta G; Furia L; Faretta MR; Brambillasca S; Quarto M; Bertero L; Boldorini R; Pollo B; Gandini S; Cora D; Minucci S; Mercurio C; Varasi M; Bonaldi T; Pelicci G
Sci Transl Med; 2021 Dec; 13(623):eabf7036. PubMed ID: 34878824
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia.
Feng Z; Yao Y; Zhou C; Chen F; Wu F; Wei L; Liu W; Dong S; Redell M; Mo Q; Song Y
J Hematol Oncol; 2016 Mar; 9():24. PubMed ID: 26970896
[TBL] [Abstract][Full Text] [Related]
9. The epigenetic promotion of osteogenic differentiation of human adipose-derived stem cells by the genetic and chemical blockade of histone demethylase LSD1.
Ge W; Liu Y; Chen T; Zhang X; Lv L; Jin C; Jiang Y; Shi L; Zhou Y
Biomaterials; 2014 Jul; 35(23):6015-25. PubMed ID: 24794925
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of lysine-specific demethylase 1 enhances the sensitivity of the chemotherapeutic drug doxorubicin in gastric cancer cell.
Zhang XY; Hao P; Wang JW; Zhao W; Liu HM; He PX
Mol Biol Rep; 2023 Jan; 50(1):507-516. PubMed ID: 36352181
[TBL] [Abstract][Full Text] [Related]
11. Novel KDM1A inhibitors induce differentiation and apoptosis of glioma stem cells via unfolded protein response pathway.
Sareddy GR; Viswanadhapalli S; Surapaneni P; Suzuki T; Brenner A; Vadlamudi RK
Oncogene; 2017 Apr; 36(17):2423-2434. PubMed ID: 27893719
[TBL] [Abstract][Full Text] [Related]
12. Development of the triazole-fused pyrimidine derivatives as highly potent and reversible inhibitors of histone lysine specific demethylase 1 (LSD1/KDM1A).
Li Z; Ding L; Li Z; Wang Z; Suo F; Shen D; Zhao T; Sun X; Wang J; Liu Y; Ma L; Zhao B; Geng P; Yu B; Zheng Y; Liu H
Acta Pharm Sin B; 2019 Jul; 9(4):794-808. PubMed ID: 31384539
[TBL] [Abstract][Full Text] [Related]
13. Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo.
Signore M; Pelacchi F; di Martino S; Runci D; Biffoni M; Giannetti S; Morgante L; De Majo M; Petricoin EF; Stancato L; Larocca LM; De Maria R; Pallini R; Ricci-Vitiani L
Cell Death Dis; 2014 May; 5(5):e1223. PubMed ID: 24810059
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of lysine-specific demethylase LSD1 induces senescence in Glioblastoma cells through a HIF-1α-dependent pathway.
Saccà CD; Gorini F; Ambrosio S; Amente S; Faicchia D; Matarese G; Lania L; Majello B
Biochim Biophys Acta Gene Regul Mech; 2019 May; 1862(5):535-546. PubMed ID: 30951900
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic compounds targeting pharmacological target lysine specific demethylase 1 and its impact on immunotherapy, chemotherapy and radiotherapy for treatment of tumor recurrence and resistance.
Agboyibor C; Dong J; Effah CY; Drokow EK; Ampomah-Wireko M; Pervaiz W; Sangmor A; Ma X; Li J; Liu HM; Zhang P
Biomed Pharmacother; 2023 Jan; 157():113934. PubMed ID: 36395607
[TBL] [Abstract][Full Text] [Related]
16. Lysine-specific demethylase (LSD1/KDM1A) and MYCN cooperatively repress tumor suppressor genes in neuroblastoma.
Amente S; Milazzo G; Sorrentino MC; Ambrosio S; Di Palo G; Lania L; Perini G; Majello B
Oncotarget; 2015 Jun; 6(16):14572-83. PubMed ID: 26062444
[TBL] [Abstract][Full Text] [Related]
17. Lysine-Specific Demethylase 1 (LSD1/KDM1A) Is a Novel Target Gene of c-Myc.
Nagasaka M; Tsuzuki K; Ozeki Y; Tokugawa M; Ohoka N; Inoue Y; Hayashi H
Biol Pharm Bull; 2019; 42(3):481-488. PubMed ID: 30828079
[TBL] [Abstract][Full Text] [Related]
18. Intrinsic and acquired drug resistance to LSD1 inhibitors in small cell lung cancer occurs through a TEAD4-driven transcriptional state.
Yan W; Chung CY; Xie T; Ozeck M; Nichols TC; Frey J; Udyavar AR; Sharma S; Paul TA
Mol Oncol; 2022 Mar; 16(6):1309-1328. PubMed ID: 34669238
[TBL] [Abstract][Full Text] [Related]
19. Preclinical studies reveal that LSD1 inhibition results in tumor growth arrest in lung adenocarcinoma independently of driver mutations.
Macheleidt IF; Dalvi PS; Lim SY; Meemboor S; Meder L; Käsgen O; Müller M; Kleemann K; Wang L; Nürnberg P; Rüsseler V; Schäfer SC; Mahabir E; Büttner R; Odenthal M
Mol Oncol; 2018 Nov; 12(11):1965-1979. PubMed ID: 30220105
[TBL] [Abstract][Full Text] [Related]
20. Histone demethylase LSD1 regulates bone mass by controlling WNT7B and BMP2 signaling in osteoblasts.
Sun J; Ermann J; Niu N; Yan G; Yang Y; Shi Y; Zou W
Bone Res; 2018; 6():14. PubMed ID: 29707403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
